Abstract:Ebola virus (EBOV) entry into host cells comprises stepwise and extensive interactions of the sole viral surface glycoprotein (GP) with multiple host factors. During the intricate process, following virus uptake and trafficking to late endosomal/lysosomal compartments, GP is proteolytically processed to cleaved GP (GPCL) by the endosomal proteases cathepsin B and L, unmasking GP's receptor-binding site. Engagement of GPCL with the universal filoviral intracellular receptor Niemann-Pick C1 (NPC1) eventually culminates in fusion between viral and cellular membranes, cytoplasmic escape of the viral nucleocapsid, and subsequent infection. Mechanistic delineation of the indispensable GPCL-NPC1-binding step has been severely hampered by the unavailability of a robust cell-based assay assessing interaction of GPCL with full-length endosomal NPC1. Here, we describe a novel in situ assay to monitor GPCL-NPC1 engagement in intact, infected cells. Visualization of the subcellular localization of binding complexes is based on the principle of DNA-assisted, antibody-mediated proximity ligation. Virus-receptor binding monitored by proximity ligation was contingent on GP's proteolytic cleavage and was sensitive to perturbations in the GPCL-NPC1 interface. Our assay also specifically decoupled detection of virus-receptor binding from steps post-receptor binding, such as membrane fusion and infection. Testing of multiple FDA-approved small-molecule inhibitors revealed that drug treatments inhibited virus entry and GPCL-NPC1 recognition by distinctive mechanisms. Together, here we present a newly established proximity ligation assay, which will allow us to dissect cellular and viral requirements for filovirus-receptor binding and to delineate the mechanisms of action of inhibitors on filovirus entry in a cell-based system.IMPORTANCE Ebola virus causes episodic but increasingly frequent outbreaks of severe disease in Middle Africa, as shown by the recently overcome second largest outbreak on record in the Democratic Republic of Congo. Despite considerable effort, FDA-approved anti-filoviral therapeutics or targeted interventions are not available yet. Virus host-cell invasion represents an attractive target for antivirals; however, our understanding of the inhibitory mechanisms of novel therapeutics is often hampered by fragmented knowledge of the filovirus-host molecular interactions required for viral infection. To help close this critical knowledge gap, here, we report an in situ assay to monitor binding of the EBOV glycoprotein to its receptor NPC1 in intact, infected cells. We demonstrate that our in situ assay based on proximity ligation represents a powerful tool to delineate receptor-viral glycoprotein interactions. Similar assays can be utilized to examine receptor interactions of diverse viral surface proteins whose studies have been hampered until now by the lack of robust in situ assays.

Transient performance and stability analysis of a hybrid grid-connected wind/PV system

Single-cell image-based genetic screens systematically identify regulators of Ebola virus subcellular infection dynamics

Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation

Development and Evaluation of a Panel of Filovirus Sequence Capture Probes for Pathogen Detection by Next-Generation Sequencing

Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics

Therapeutic strategies to target the Ebola virus life cycle

Filovirus vaccines as a response paradigm for emerging infectious diseases

Recent Advances in Therapeutic Approaches Against Ebola Virus Infection

Ebola virus outbreak, updates on current therapeutic strategies

High Content Image-Based Screening of a Protease Inhibitor Library Reveals Compounds Broadly Active against Rift Valley Fever Virus and Other Highly Pathogenic RNA Viruses

The use of an Ebola virus reporter cell line in a semi-automated microtitration assay

A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition

Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo.

Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future

Pseudotyped Viruses for Marburgvirus and Ebolavirus

Treatment-focused Ebola trials, supportive care and future of filovirus care

Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines

Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery

Multiplexed multicolor antiviral assay amenable for high-throughput research

Non-Ebola Filoviruses: Potential Threats to Global Health Security